Heading to 50 cents!!! The shareholders would like to thank Leo for continuing his 420K salary while the shareholders lose major equity. Down 40 percent in 2017 the year of partnerships. With P interim cancelled, K taking forever (10 patient trial) and UP/ABSSSI frozen Leo has conned the biotech world another year. Can't wait for the next presentation or show event!!!
Business development is not a straight line believe me. It's the final outcome(s) that's important. If you don't like it that's your prerogative but as an investor I'm glad to be here.